

10/569337

Express Mail No. EV 686 022 608 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Alexander C. Chang

IAD20 PCT/US2004/027155 Confirmation No.: To be determined

Serial No.: To be assigned, national stage of
PCT/US2004/027155 Art Unit: To be determined

Filed: August 19, 2004 Examiner: To be determined

For: ECG MONITORING METHODS Attorney Docket No.: 105998-999003
AND APPARATUS (11393-004-999)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
 - 1a. A list of all patents, publications, applications, or other information submitted for consideration by the office.
 - 1b. A legible copy of:
 - Each publication or that portion which caused it to be listed on the PTO-1449;
 - For each cited pending unpublished U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion that have been checked to be unavailable at the USPTO's private PAIR system;
 - An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report;
 - Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications;
 - All other information or portion which caused it to be listed on the PTO-1449.
 - 1c. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and U.S. patent application publications are not submitted herewith unless required by the office.
 - 1d. Pursuant to 1287 OG 163, copies of cited pending unpublished applications that are available at the USPTO's private PAIR system are not submitted herewith.
2. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):

- Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
 - Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - Before the mailing of the first Office action on the merits;
 - Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.
- (Check either Item 3a or 3b)*
- 3a. The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
 - enclosed.
 - to be charged to Jones Day Deposit Account No. 50-3013.
- (Item 3b to be checked if any reference known for more than 3 months)*
4. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.
- The Certification Statement in Item 5 below is applicable.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- enclosed.
- to be charged to Jones Day Deposit Account No. 50-3013.


5. Certification Statement (applicable if Item 3a or Item 4 is checked):
- (Check either Item 5a or 5b)*
- 5a. In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

10/569332

IAP20 Rec'd PCT/PTO 21 FEB 2006

6. This application is a continuation application under 37 C.F.R. §1.53(b) or (d).
(Check appropriate Items 6a, 6b and/or 6c)
- 6a. A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7. This is a Supplemental Information Disclosure Statement. (Check Item 7a)
- 7a. This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8. In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
(Check Item 8a, 8b, or 8c)
- 8a. Satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. Set forth in the application.
- 8c. Enclosed as an attachment hereto.
9. The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.
10. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,


Brett Lovejoy
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

42,813

(Reg. No.)

Date: February 21, 2006

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO.	APPLICATION NO 10/1569337 To be assigned U.S. national stage of PCT/US2004/027155
		11393-004-999	APPLICANT Chang
		FILING DATE Herewith	GROUP To be determined

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A01	3,612,061	10/12/71	Collins et al.			
A02	4,121,575	10/24/78	Mills et al.			
A03	4,233,987	11/18/80	Feingold			
A04	4,328,814	05/11/82	Arkans			
A05	4,583,549	04/22/86	Manoli			
A06	4,763,660	08/16/88	Kroll et al.			
A07	4,852,572	08/01/89	Nakahashi et al.			
A08	4,955,381	09/11/90	Way et al.			
A09	4,957,109	09/18/90	Groeger et al.			
A10	5,042,481	08/27/91	Suzuki et al.			
A11	5,080,099	01/14/92	Way et al.			
A12	5,184,620	02/09/93	Cudahy et al.			
A13	5,191,886	03/09/93	Paeth et al.			
A14	5,299,119	03/29/94	Kraf et al.			
A15	5,327,888	06/12/94	Imran			
A16	5,341,806	08/30/94	Gadsby et al.			
A17	5,503,158	04/02/96	Coppock et al.			
A18	5,507,290	04/16/96	Kelly et al.			
A19	5,678,545	10/21/97	Stratbucker			
A20	5,685,303	11/11/97	Rollman et al.			
A21	5,724,580	03/03/98	Levin et al.			
A22	5,782,238	07/21/98	Beitler			
A23	5,868,671	02/09/99	Mahoney			
A24	5,916,159	06/29/99	Kelly et al.			
A25	5,938,597	08/17/99	Stratbucker			
A26	6,052,615	04/18/00	Field et al.			
A27	6,076,003	06/13/00	Rogel			
A28	6,115,623	09/05/00	McFee			
A29	6,205,346 B1	03/20/01	Akiva			
A30	6,217,525 B1	04/17/01	Medema et al.			
A31	6,400,975 B1	06/04/02	McFee			
A32	6,415,169 B1	07/02/02	Kornrumpf et al.			
A33	6,453,186 B1	09/17/02	Lovejoy et al.			
A34	6,496,705 B1	12/17/02	Ng et al.			

FOREIGN PATENT DOCUMENTS

IAP20 REC'D 21 FEB 2006

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
						NO

OTHER REFERENCES (*Including Author, Title, Date, Pertinent Pages, Etc.*)

C01	Griffin and Kaplan, 1987, Anaesthesia 42, pp 155-159.
C02	Kaplan, <i>Cardiac Anaesthesia</i> , 3 rd edition, 1993, pp. 111-116, 299-341.
C03	www.gmedinc.com/scientificbasiswebversion1.pdf, last accessed July 2, 2003.
C04	<i>Guide to Clinical Preventive Services</i> , Second Edition, U.S. Department of Health and Human Services, Section One, pp. 1-14.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.